50 research outputs found
Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS
Adrenomedullin
(ADM) is upregulated independently by hypoxia and LPS, two key
factors in the pathogenesis of acute lung injury (ALI). This study
evaluates the expression of ADM in ALI using experimental models
combining both stimuli: an in vivo model of rats treated with LPS and
acute normobaric hypoxia (9% O2) and an in vitro model of rat lung
cell lines cultured with LPS and exposed to hypoxia (1% O2). ADM
expression was analyzed by in situ hybridization, Northern blot,
Western blot, and RIA analyses. In the rat lung, combination of
hypoxia and LPS treatments overcomes ADM induction occurring
after each treatment alone. With in situ techniques, the synergistic
effect of both stimuli mainly correlates with ADM expression in
inflammatory cells within blood vessels and, to a lesser extent, to cells
in the lung parenchyma and bronchiolar epithelial cells. In the in vitro
model, hypoxia and hypoxia LPS treatments caused a similar strong
induction of ADM expression and secretion in epithelial and endothelial
cell lines. In alveolar macrophages, however, LPS-induced
ADM expression and secretion were further increased by the concomitant
exposure to hypoxia, thus paralleling the in vivo response. In
conclusion, ADM expression is highly induced in a variety of key
lung cell types in this rat model of ALI by combination of hypoxia and
LPS, suggesting an essential role for this mediator in this syndrom
Effects of acute hypoxia and lipopolysaccharide on nitric oxide synthase-2 expression in acute lung injury
The potential role of nitric oxide synthase-2 (NOS2) in acute lung
injury (ALI) has gained increasing attention. This study evaluates
the effects of hypoxia, an important feature of ALI, on NOS2 expression
in a rat model of ALI caused by exposure to hypoxia and LPS.
Exposure to hypoxia alone had no effect on the expression of NOS2
in rat lungs. LPS treatment resulted in a significant increase in NOS2
in the lungs, which was further enhanced by concomitant exposure
to hypoxia. Immunohistochemical analysis and in situ hybridization
showed no changes in the expression of NOS2 in lung resident cells
under any conditions. The increase in NOS2 levels is mainly due to
the influx of NOS2-expressing inflammatory cells. By morphologic
analysis, these inflammatory cells were identified as neutrophils,
lymphocytes, and monocytes. In vitro experiments of lung epithelial
and endothelial cell lines showed no detectable expression of NOS2
with any of the treatments. In a macrophage cell line, LPS-induced
NOS2 expression was not affected by the concomitant exposure to
hypoxia. In conclusion, LPS increases NOS2 expression in rat lungs
through the recruitment of NOS2-producing leukocytes. Simultaneous
exposure to LPS and hypoxia results in a greater influx of inflammatory
cells that further enhances NOS2 expression
TGFBI expression is associated with a better response to chemotherapy in NSCLC
<p>Abstract</p> <p>Background</p> <p>Lung cancer is one of the most prevalent neoplasias in developed countries. Advances in patient survival have been limited and the identification of prognostic molecules is needed. Resistance to treatment is strongly related to tumor cell adhesion to the extracellular matrix and alterations in the quantity and nature of molecules constituting the tumor cell niche. Recently, transforming growth factor beta-induced protein (TGFBI), an extracellular matrix adaptor protein, has been reported to be differentially expressed in transformed tissues. Loss of TGFBI expression has been described in several cancers including lung carcinoma, and it has been suggested to act as a tumor suppressor gene.</p> <p>Results</p> <p>To address the importance of TGFBI expression in cancer progression, we determined its expression in NSCLC clinical samples using immunohistochemistry. We identified a strong association between elevated TGFBI expression and the response to chemotherapy. Furthermore, we transiently over-expressed and silenced TGFBI in human NSCLC cell lines. Cells over-expressing TGFBI displayed increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine. We observed that TGFBI-mediated induction of apoptosis occurred through its binding to αvβ3 integrin. We also determined that full-length TGFBI did not induce caspase 3/7 activation but its proteolytic fragments that were < 3 kDa in size, were able to activate caspase 3, 7 and 8. This pro-apoptotic effect was blocked by anti-αvβ3 integrin antibodies.</p> <p>Conclusions</p> <p>The results shown here indicate that TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy.</p
Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients
Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are NAD+-dependent protein deacetylases involved in the regulation of key cancer-associated genes. In this study we evaluated the relevance of these deacetylases in lung cancer biology
Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens
<p>Abstract</p> <p>Background</p> <p>The accurate normalization of differentially expressed genes in lung cancer is essential for the identification of novel therapeutic targets and biomarkers by real time RT-PCR and microarrays. Although classical "housekeeping" genes, such as GAPDH, HPRT1, and beta-actin have been widely used in the past, their accuracy as reference genes for lung tissues has not been proven.</p> <p>Results</p> <p>We have conducted a thorough analysis of a panel of 16 candidate reference genes for lung specimens and lung cell lines. Gene expression was measured by quantitative real time RT-PCR and expression stability was analyzed with the softwares <it>GeNorm </it>and <it>NormFinder</it>, mean of |ΔCt| (= |Ct Normal-Ct tumor|) ± SEM, and correlation coefficients among genes. Systematic comparison between candidates led us to the identification of a subset of suitable reference genes for clinical samples: IPO8, ACTB, POLR2A, 18S, and PPIA. Further analysis showed that IPO8 had a very low mean of |ΔCt| (0.70 ± 0.09), with no statistically significant differences between normal and malignant samples and with excellent expression stability.</p> <p>Conclusion</p> <p>Our data show that IPO8 is the most accurate reference gene for clinical lung specimens. In addition, we demonstrate that the commonly used genes GAPDH and HPRT1 are inappropriate to normalize data derived from lung biopsies, although they are suitable as reference genes for lung cell lines. We thus propose IPO8 as a novel reference gene for lung cancer samples.</p
Identification of importin (IPO-8) as the most accurate reference gene for the clinicopathological analysis of lung specimens
Abstract
Background: The accurate normalization of differentially expressed genes in lung cancer is
essential for the identification of novel therapeutic targets and biomarkers by real time RT-PCR
and microarrays. Although classical "housekeeping" genes, such as GAPDH, HPRT1, and beta-actin
have been widely used in the past, their accuracy as reference genes for lung tissues has not been
proven.
Results: We have conducted a thorough analysis of a panel of 16 candidate reference genes for
lung specimens and lung cell lines. Gene expression was measured by quantitative real time RTPCR
and expression stability was analyzed with the softwares GeNorm and NormFinder, mean of
|ΔCt| (= |Ct Normal-Ct tumor|) ± SEM, and correlation coefficients among genes. Systematic
comparison between candidates led us to the identification of a subset of suitable reference genes
for clinical samples: IPO8, ACTB, POLR2A, 18S, and PPIA. Further analysis showed that IPO8 had
a very low mean of |ΔCt| (0.70 ± 0.09), with no statistically significant differences between normal
and malignant samples and with excellent expression stability.
Conclusion: Our data show that IPO8 is the most accurate reference gene for clinical lung
specimens. In addition, we demonstrate that the commonly used genes GAPDH and HPRT1 are
inappropriate to normalize data derived from lung biopsies, although they are suitable as reference
genes for lung cell lines. We thus propose IPO8 as a novel reference gene for lung cancer samples
Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
Abstract
Background
Microarrays strategies, which allow for the characterization of thousands of alternative splice forms in a single test, can be applied to identify differential alternative splicing events. In this study, a novel splice array approach was developed, including the design of a high-density oligonucleotide array, a labeling procedure, and an algorithm to identify splice events.
Results
The array consisted of exon probes and thermodynamically balanced junction probes. Suboptimal probes were tagged and considered in the final analysis. An unbiased labeling protocol was developed using random primers. The algorithm used to distinguish changes in expression from changes in splicing was calibrated using internal non-spliced control sequences. The performance of this splice array was validated with artificial constructs for CDC6, VEGF, and PCBP4 isoforms. The platform was then applied to the analysis of differential splice forms in lung cancer samples compared to matched normal lung tissue. Overexpression of splice isoforms was identified for genes encoding CEACAM1, FHL-1, MLPH, and SUSD2. None of these splicing isoforms had been previously associated with lung cancer.
Conclusions
This methodology enables the detection of alternative splicing events in complex biological samples, providing a powerful tool to identify novel diagnostic and prognostic biomarkers for cancer and other pathologies
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non–small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer.
Objectives: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) genetic alteration as a therapeutic target and predictive biomarker of response to dasatinib in NSCLC.
Methods: Functional significance was evaluated by in vivo models of NSCLC and metastasis and patient-derived xenografts. The efficacy of pharmacological and genetic (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also evaluated. In vitro functional assays for signaling, survival, and invasion were also performed. The association between YES1 alterations and prognosis was evaluated in clinical samples.
Measurements and Main Results: We demonstrated that YES1 is essential for NSCLC carcinogenesis. Furthermore, YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. YES1 effects were mainly driven by mTOR (mammalian target of rapamycin) signaling. Interestingly, cell lines and patient-derived xenograft models with YES1 gene amplifications presented a high sensitivity to dasatinib, an SFK inhibitor, pointing out YES1 status as a stratification biomarker for dasatinib response. Moreover, high YES1 protein expression was an independent predictor for poor prognosis in patients with lung cancer.
Conclusions: YES1 is a promising therapeutic target in lung cancer. Our results provide support for the clinical evaluation of dasatinib treatment in a selected subset of patients using YES1 status as predictive biomarker for therapy
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations
BACKGROUND: The development of a more refined prognostic methodology for early non-small cell lung cancer (NSCLC) is an unmet clinical need. An accurate prognostic tool might help to select patients at early stages for adjuvant therapies. RESULTS: A new integrated bioinformatics searching strategy, that combines gene copy number alterations and expression, together with clinical parameters was applied to derive two prognostic genomic signatures. The proposed methodology combines data from patients with and without clinical data with a priori information on the ability of a gene to be a prognostic marker. Two initial candidate sets of 513 and 150 genes for lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively, were generated by identifying genes which have both: a) significant correlation between copy number and gene expression, and b) significant prognostic value at the gene expression level in external databases. From these candidates, two panels of 7 (ADC) and 5 (SCC) genes were further identified via semi-supervised learning. These panels, together with clinical data (stage, age and sex), were used to construct the ADC and SCC hazard scores combining clinical and genomic data. The signatures were validated in two independent datasets (n = 73 for ADC, n = 97 for SCC), confirming that the prognostic value of both clinical-genomic models is robust, statistically significant (P = 0.008 for ADC and P = 0.019 for SCC) and outperforms both the clinical models (P = 0.060 for ADC and P = 0.121 for SCC) and the genomic models applied separately (P = 0.350 for ADC and P = 0.269 for SCC). CONCLUSION: The present work provides a methodology to generate a robust signature using copy number data that can be potentially used to any cancer. Using it, we found new prognostic scores based on tumor DNA that, jointly with clinical information, are able to predict overall survival (OS) in patients with early-stage ADC and SCC